Introduction {#Sec1}
============

Anaphylaxis, the most severe manifestation of an acute allergic reaction, is a medical emergency and in rare cases may cause death \[[@CR25]\]. It typically involves two or more body systems including skin and/or mucosa, upper and lower respiratory tract, gastrointestinal tract, cardiovascular system, and central nervous system \[[@CR25]\]. First-line treatment for anaphylaxis is intramuscular (IM) epinephrine injection in the anterolateral thigh \[[@CR25]\]. Pediatric emergency department (ED) visits for children with anaphylaxis increased from 5.7 to 11.7 per 10,000 visits from 2009 to 2013 in the USA \[[@CR14], [@CR20]\], and this has become an important health issue. The most common causes of anaphylaxis in children are allergies to foods, followed by medications, stinging insect venom, blood products, immunotherapy, latex, vaccines, and contrast media \[[@CR13], [@CR33]\].

Despite drug-induced anaphylaxis (DIA) being the second most common cause of pediatric anaphylaxis \[[@CR12]\], information on its characteristics and management is limited, and data on DIA in children outside the USA and Europe is sparse. Here, we present an analysis of 91 pediatric DIA cases based on data extracted from the Beijing Pharmacovigilance Database (BPD) from 2004 to 2014. The purpose of the study was to evaluate the elicitors, describe the main clinical manifestations of anaphylaxis and treatment of DIA in pediatric patients.

Materials and methods {#Sec2}
=====================

Study participants {#Sec3}
------------------

This study was considered to be exempt from further review by the Institutional Review Board, Peking University Third Hospital. We utilized the BPD provided by the Beijing Center for Adverse Drug Reaction Monitoring (BCADR) for this study. A total of 94 participating hospitals in the Beijing region are required to report severe adverse drug event (ADE) cases to this database. Cases are self-reported to the respective pharmacy department by physicians, nurses, and pharmacists. The BPD is created to collect well-defined and standardized data of affected patients experiencing ADEs in the Beijing region of China. We identified all patients with a reported drug-induced acute allergic reaction or anaphylaxis using the following search terms: "anaphylaxis," "anaphylactic shock," "allergy," "allergic reaction," and "hypersensitivity" from the BPD database for the period covering January 1, 2004 to December 31, 2014. A data extraction form was developed to validate the diagnosis and severity of anaphylaxis and the use of epinephrine. The form was tested and revised based on a pilot analysis of database records from 250 patients. Two trained extractors performed the extraction independently to ensure consistency, and discrepancies were resolved by an experienced investigator with expertise in standardized medical record extraction. Two physician adjudicators independently determined the diagnosis of anaphylaxis and assessed the case severity based on the information extracted from each case. All disagreements were resolved through discussions. We divided the severity of each anaphylaxis case into either mild to moderate or severe categories (Appendix [1](#MOESM1){ref-type="media"}) \[[@CR3]\]. The information on BCADR, detailed case query strategy and data extraction from our research team has been previously published \[[@CR32], [@CR34]\], in which a cohort of 1189 DIA patients were identified. A subgroup of pediatric patients (less than 18 years of age) from the base cohort was included in this analysis.

Study design {#Sec4}
------------

Patient's age was categorized into three strata: 0--5, 6--12, and 13--17 years. We investigated differences between groups with regards to admission diagnosis, suspected elicitors, organ systems' involvement, and therapies to treat anaphylaxis. We analyzed the dose and the administration route (intravenous IV, IM, and subcutaneous SC) of epinephrine. To analyze the supratherapeutic dosing of epinephrine, initial pediatric epinephrine dosing was categorized into non-supratherapeutic or supratherapeutic \[[@CR11], [@CR17]\] as determined by weight-based dosing (≤ 0.01 mg/kg vs \> 0.01 mg/kg of 1:1000 solution with a maximum dose of 0.5 mg for IM and SC routes, and or 0.001 mg/kg for IV bolus with a maximum dose of 0.1 mg of 1:10,000 solution). When weights were not available, we assessed the pediatric IM/SC epinephrine dosing based on age groups (\<6, 6--12, and \>12 years) \[[@CR28]\], and for IV bolus we used age to estimate body weight \[[@CR31]\] to calculate the dose. We did not analyze supratherapeutic dosing with epinephrine IV continuous infusion as it is usually titrated to clinical effects, and not all the necessary information for calculating the total dose was available, such as the exact time for dose modifications.

We compared the baseline information, anaphylactic symptoms, outcome for patients receiving epinephrine monotherapy, corticosteroid monotherapy, as well as epinephrine and corticosteroid combination therapy. We also compared outcomes between patients who received epinephrine as an initial treatment and patients who did not receive it as an initial treatment.

Statistical analyses {#Sec5}
--------------------

The statistical analysis was performed using the SPSS version 18 (SPSS Inc., IL, USA). Dosing data across age groups were expressed as median (min, max) and compared using the Kruskal-Wallis test, depending on non-normality. If the *P* value of the Kruskal-Wallis test is less than 0.05, the Wilcoxon rank sum test was conducted for pairwise comparisons between groups. The dichotomous variables were described as frequency (percentage) and differences from age groups were compared using the Pearson's chi-square test (when no cell in the table have an expected count less than 1, and no more than 20% of the cells should have an expected count less than 5) or the Fisher's exact test. The *P* values of pairwise comparisons were adjusted by the Bonferroni correction for multiple comparisons. All tests were two-tailed tests, where a difference with *P* \< 0.05 was considered to be statistically significant.

### Data availability {#FPar1}

The data that support the findings of this study are available from the BCADR, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission from the BCADR.

Results {#Sec6}
=======

Patients and anaphylaxis elicitors {#Sec7}
----------------------------------

A total of 9425 patients with drug-induced hypersensitivity reactions were identified from the BPD using our search terms, and 91 pediatric patients were ultimately included in our analysis (flowchart is shown in Appendix [2](#MOESM1){ref-type="media"}). The majority of patients (88, 97%) developed anaphylaxis during their hospitalizations, and 3 patients presented to an ED. Of the 88 inpatients, the number of patients who received anaphylaxis treatment in EDs and non-ED settings were 11(13%) and 77(88%), respectively. Of the 91 patients, 35% were 0--5 year old, 26% were 6--12 year old, and 39% were 13--17 year old; and 62% of the patients were males (Table [1](#Tab1){ref-type="table"}). There were no significant differences for admission diagnoses and elicitors among the three age groups, except for a significant difference between the 6--12 years group and 13--17 years group for biologics use (*P* = 0.032).Table 1Demographics, original diseases, and elicitors of DIA in children by age groupAll no. (%) (*n* = 91)0--5 years no. (%) (*n* = 32)6--12 years no. (%) (*n* = 24)13--17 years no. (%) (*n* = 35)*χ* ^2^*P* \*Demographics Male56(62)20(63)11(46)25(71)3.9600.138 Female35(39)12(38)13(54)10(29)Admission diagnoses Infectious49(54)20(63)12(50)17(49)1.4990.473 RTI38(42)18(56)8(33)12(34)4.2670.118 Stress/operation/trauma15(17)3(9)2(8)10(29)0.061 Tumor10(11)4(13)3(13)3(9)0.837 Gastrointestinal disease8(9)3(9)2(8)3(9)1.000 Rheumatological disease4(4)2(6)2(8)0(0)0.184 Asthma1(1)0(0)1(4)0(0)0.264 Cardiovascular disease2(2)0(0)0(0)2(6)0.334 Other diseases†0(0)0(0)0(0)0(0)--Elicitors Antibiotics48(53)17(53)14(58)17(49)0.5470.761 Cephalosporins31(34)13(41)10(42)8(23)3.1880.203 Macrolides7(8)1(3)3(13)3(9)0.421 Penicillins3(3)0(0)1(4)2(6)0.479 Other antibiotics‡7(8)3(9)0(0)4(11)0.282 TCM injection¶8(9)2(6)1(4)5(14)0.453 Biologics7(8)1(3)0(0)6(17)0.032 Radiocontrast agents4(4)0(0)3(13)1(3)0.088 Glucocorticoids3(3)0(0)1(4)2(6)0.479 Chemotherapeutic agents3(3)1(3)1(4)1(3)1.000 Anesthetics3(3)3(9)0(0)0(0)0.057 IV mucosolvan2(2)2(7)0(0)0(0)0.189 Antivirus1(1)1(3)0(0)0(0)0.615 Vaccine0(0)0(0)0(0)0(0)---- NSAIDs0(0)0(0)0(0)0(0)---- Others§11(12)4(13)4(17)3(9)0.606*RTI*, respiratory tract infection; *TCM*, Traditional Chinese medicine; *IV*, intravenous; *NSAIDs*, non-steroid anti-inflammatory drugs\**P* values are from Fisher's exact test or Pearson's chi-square test of difference across age groups†Other diseases including 1 patient with epilepsy, 1 patient with cerebral palsy, and 1 patient with short stature‡Other antibiotics include 3 patients on levofloxacin, 2 patients on vancomycin, 1 patient on lincomycin, and 1 patient on metronidazole¶The 8 TCM injections are Qingkailing, Shuanghuanglian, Houttuynia, Xiyanping, Xingnaojing, Ligustrazine, and Dehydroandrograpolide (for 2 cases)§Other medications include calcium dibutyryladenosine cyclophosphate for injection, etamsylate injection, hydroxyethyl starch 200/0.5200/0.5), succinylated gelatin injection, a coenzyme A for injection, levobunolol hydrochloride ophthalmic solution, vitamin K1 injection, colloidal aluminum phosphate gel, fat-soluble vitamin(1) for injection

Clinical features {#Sec8}
-----------------

The majority of patients with anaphylaxis experienced cardiovascular and respiratory symptoms, and approximately half of the patients developed mucocutaneous manifestations (Table [2](#Tab2){ref-type="table"}). Notably, the 0--5 years group was more likely to develop cyanosis than the 13--17 years group (OR = 5.14, 95%CI \[1.74, 15.20\], *P* = 0.002), whereas the 13--17 years group were more likely to develop hypotension than the 6--12 years group (OR = 11.79, 95%CI \[2.28, 60.87\], *P* = 0.002) and neurological symptoms than the 0--5 years group (OR = 3.56, 95%CI \[1.26, 10.08\], *P* = 0.015). The 13--17 years group was also more likely to develop severe anaphylaxis (OR = 15.46, 95%CI \[1.85, 129.33\], *P* = 0.002).Table 2Clinical manifestations during anaphylaxis reactions of children by age groupAll no. (%) (*n* = 91)0--5 years no. (%) (*n* = 32)6--12 years no. (%) (*n* = 24)13--17 years no. (%) (*n* = 35)*χ* ^2^*P* \*Mucocutaneous54(59)22(69)14(58)18(51)2.0920.351 Flushing21(23)11(34)4(17)6(17)3.5510.169 Pruritus16(18)4(13)5(21)7(20)0.649 Diffuse urticaria33(36)13(41)8(33)12(34)0.4120.814 Angioedema10(11)4(13)3(13)3(9)0.837 Conjunctivitis9(10)2(6)3(13)4(11)0.742Respiratory system66(73)25(78)19(79)22(63)2.6770.265 Rhinorrhea1(1)0(0)1(4)0(0)0.264 Cough3(3)0(0)0(0)3(9)0.111 Voice change3(3)0(0)1(4)2(6)0.479 Dyspnea22(24)7(22)7(29)8(23)0.5170.822 Wheezing21(23)7(22)7(29)7(20)0.7720.704 Cyanosis36(40)18(56)11(46)7(20)9.7240.008 Respiratory arrest2(2)1(3)0(0)1(3)1.000 Hypoxemia8(9)2(6)4(17)2(6)0.368Cardiovascular system71(78)23(72)15(63)33(94)9.4760.009 Hypotension69(76)22(69)14(58)33(94)11.3860.003 Cardiac arrest1(1)0(0)0(0)1(3)1.000 Incontinence3(3)0(0)1(4)2(6)0.479Gastrointestinal system33(36)10(31)10(42)13(37)0.6630.718 Emesis27(30)8(25)9(38)10(29)1.0600.589 Nausea12(13)0(0)5(21)7(20)0.010 Abdominal cramping13(14)5(16)5(21)3(9)0.382 Diarrhea0(0)0(0)0(0)0(0)----Neurological system35(39)8(25)8(33)19(54)6.4200.040 Presyncope22(24)6(19)6(25)10(29)0.8920.640 Syncope17(19)6(19)2(8)9(26)0.254 Convulsion4(4)1(3)0(0)3(9)0.447Severity of anaphylaxis Mild to moderate15(17)10(31)4(17)1(3)0.005 Severe76(84)22(69)20(83)34(97)Outcome Death1(1)0(0)0(0)1(3)1.000 ICU admission7(8)4(13)2(8)1(3)0.325*ICU*, intensive care unit\**P* values are from Fisher's exact test or Pearson's chi-square test of difference across age groups

Analysis of therapies for the treatment of anaphylaxis {#Sec9}
------------------------------------------------------

A total of 62 patients (68%) received epinephrine for anaphylaxis, but only 49 (54%) received it as an initial treatment. Forty-eight patients had an adequate documentation of administration routes; the number of patients who received IM, SC, IV bolus injection, and IV continuous infusion were 11 (23%), 16 (33%), 15 (31%), and 6 (13%), respectively. Thirty-seven patients had a clear documentation for both the administration route and dosing of epinephrine. A total of 73 (80%) patients received corticosteroids and 68 (75%) received corticosteroid as initial therapy including 34 (37%) on corticosteroid alone and the other 34 (37%) on both corticosteroid and epinephrine. A total 29 (32%) patients received antihistamines, and only 4 (4%) patients received bronchodilators. There was no significant difference among the three different age groups with regards to the route of administration for epinephrine, the route of administration for corticosteroids, or the initial drug therapy of anaphylaxis (Appendix [3](#MOESM1){ref-type="media"}).

Analysis of initial administration routes and initial dosing of epinephrine {#Sec10}
---------------------------------------------------------------------------

A total of 49 patients received epinephrine as initial therapy, including 15 (17%) on epinephrine alone and 34 (37%) on both epinephrine and corticosteroid. Among the 49 patients, data were available from 37 patients with clearly documented initial administration routes of epinephrine and severities of anaphylaxis. The percentage with IM injection, SC injection, IV bolus and IV continuous infusion route was 26, 40, 26, and 9%, respectively. There was no significant difference for number of patients by each administration route (*P* = 0.074). Overall, there was no significant difference in terms of anaphylaxis severity between each administration route (*P* = 0.940). There was a significant difference regarding the frequency of supratherapeutic dosing of epinephrine by each administration route (*χ* ^2^ = 10.407, *P* = 0.005) (Table [3](#Tab3){ref-type="table"}). A supratherapeutic dosing was more likely with the IV bolus route (11/12) compared to IM (5/14, OR = 19.25, 95%CI \[1.77, 209.55\], *P* = 0.009), and SC (4/11, OR = 19.80, 95%CI \[1.94, 201.63\], *P* = 0.005). The anaphylaxis severity was not associated with supratherapeutic dosing by an administration route (*χ* ^2^ = 1.481, *P* = 0.512) (Table [3](#Tab3){ref-type="table"}). There was no difference by age in the anaphylaxis treatment and administration for epinephrine.Table 3Dosing and route of epinephrine administration associated with severity of anaphylaxisSeverity of anaphylaxisIM injection, no. (%) (*n* = 11)SC injection, no. (%) (*n* = 14)IV bolus, no. (%) (*n* = 12)Supratherapeutic dosingRecommended dosing*P*Supratherapeutic dosingRecommended dosing*P*Supratherapeutic dosingRecommended dosing*P*Mild to moderate1(25)2(29)1.0002(40)1(11)0.5050(0)1(100)0.083Severe3(75)5(71)3(60)8(89)11(100)0(0)*P* values are from Fisher's exact test of difference across age groups. Data were available from 37 patients with clearly documented administration routes (IM injection, SC injection, and IV bolus) and dose of epinephrine. Overall, there is no significant difference regarding the severity of anaphylaxis in each administration route (*P* = 0.512). There was no significant difference between the percentage of severe anaphylaxis between recommended and supratherapeutic dosing groups in each administration route group (*P* value is 1.000, 0.505, and 0.083 for IM, SC, and IV bolus, respectively). Overall, there is a significant difference regarding the overdose rate in each administration route (*P* = 0.005). IV bolus is more likely associated with supratherapeutic dose compared to IM injection (*P* = 0.009) and SC injection (*P* = 0.005). There is no significant difference in overdose rate between IM injection and SC injection (*P* = 1.000)

A total of 20 (54%) patients received supratherapeutic dosing of epinephrine (Table [4](#Tab4){ref-type="table"}). Thirteen patients were overdosed according to the maximum dose of the corresponding administration routes, dosing for 11 patients with IV bolus route exceeded the maximum dose of 0.1 mg, and dosing for 2 patients with IM route exceeded the maximum dose of 0.5 mg. Seven patients under 6 years old were overdosed according to maximum dose of 0.15 mg for this age group (Table [4](#Tab4){ref-type="table"}).Table 4The information of 20 epinephrine-supratherapeutic dosing pediatric patientsNumberAge (years)Epinephrine as an initial treatment\*Route of epinephrineDose of epinephrine (mg)12.5YIV bolus0.5024.0YIV bolus0.5034.2YIV bolus3.0049.0NIV bolus0.50510.0NIV bolus0.30610.2YIV bolus1.00713.0YIV bolus0.50814.2NIV bolus0.50914.9NIV bolus0.501015.1NIV bolus1.001117.9YIV bolus0.20124.0YIM0.20134.7YIM0.33148.5NIM1.001517.2YIM1.00162.0YSC0.30173.7YSC0.50183.8YSC0.30194.0YSC0.30205.8YSC0.40\*Y, epinephrine as an initial treatment; N, epinephrine not as an initial treatment

Among 91 cases, only 1 patient died and this patient was treated initially with epinephrine; 7 patients were admitted to ICU, of those 4 patients received epinephrine (2 were initially treated) and 2 were treated with supratherapeutic doses. There was no significant difference regarding outcome between patients who received epinephrine as an initial treatment and those who did not (*χ* ^2^ = 4.437, *P* = 0.229, Appendix [4](#MOESM1){ref-type="media"}). Overall, our analysis showed there were no significant association between symptoms and use of epinephrine, whether use epinephrine as an initial treatment, or administration route of epinephrine (Appendix [5](#MOESM1){ref-type="media"}--[7](#MOESM1){ref-type="media"}).

Discussion {#Sec11}
==========

Using the BPD data, our study is the first to analyze the clinical features and treatment of pediatric DIA patients in clinical settings over a decade in Beijing, China. A total of 91 pediatric cases were identified and assessed, accounting for 7.7% (91/1189) of both adult and pediatric DIA patients. Antibiotics, TCM injections and biologics were the top three drug triggers. The most common anaphylactic clinical features were manifestations of the cardiovascular and respiratory systems, and children may present signs and symptoms differently based on age groups. Epinephrine is underutilized, and only 54% receive it as the initial treatment. Only 23% of patients received epinephrine by the IM route, suggesting the administration route is not appropriate. The percentage of supratherapeutic dose of epinephrine is high, 92% (11/12) for the IV bolus, and 36% (5/14) for IM, and 36% (4/11) for SC. Furthermore, the overdose frequency of IV bolus was significantly higher than both IM and SC combined.

Demographics and elicitors of pediatric patients with DIA {#Sec12}
---------------------------------------------------------

The higher frequency for males in the 0--5 year and the 13--17 year age groups is consistent with the data from the European anaphylaxis registry \[[@CR10]\] reporting that boys are more likely to experience anaphylaxis. Infectious diseases, stress/operation/trauma and tumor were the principal admission diagnoses; disease distribution was similar among the three age groups. Although asthma is considered to be one of the important risk factors for anaphylaxis \[[@CR9], [@CR15]\], there was only one case with a current asthma diagnosis in our study, possibly related to our small sample size or the relatively low prevalence of asthma in China \[[@CR22]\].

Antibiotics were the most common trigger, which is in line with a few previous studies indicating antibiotics are the most common cause of DIA \[[@CR9], [@CR19], [@CR23]\]. Our study suggests that clinical signs and symptoms related to anaphylaxis should be closely monitored when children are administered antibiotics in the hospital setting, particularly β-lactams. Unlike the US or the European reports, TCM injections were the next most common cause of DIA, including *Qingkailing*, *Shuanghuanglian*, *Houttuynia*, etc., which is consistent with a recent study from China \[[@CR16]\]. TCM injections have relatively complex formulations and may cause anaphylaxis \[[@CR5], [@CR16]\], thus they should be avoided if possible. Although non-steroidal anti-inflammatory drugs (NSAIDs) are important triggers for DIA in adults \[[@CR1], [@CR6]\], our analysis did not observe any NSAID-induced anaphylaxis, which is consistent with a previous study reporting that NSAIDs were infrequent causes of pediatric anaphylaxis \[[@CR19]\].

Target organ involvement and clinical manifestations during anaphylaxis reactions of DIA children {#Sec13}
-------------------------------------------------------------------------------------------------

The two most frequent clinical features of DIA in our study were overall cardiovascular and respiratory manifestations, followed by mucocutaneous symptoms. Although mucocutaneous symptoms are generally considered as a typical sign of allergy, our study implies that absence of such symptoms might not be sufficient to exclude the diagnosis of anaphylaxis. Among three age groups, we observed significant differences for some symptoms (neurological systems, cyanosis, hypotension, and nausea) and anaphylaxis severity, which is in line with previous studies that observed age-related patterns in the clinical presentation of pediatric anaphylaxis \[[@CR10], [@CR24]\]. Considering age differences regarding DIA, symptoms could facilitate early recognition and prompt treatment of this potentially life-threatening condition.

The present study found that 36% of DIA children had gastrointestinal manifestations, with emesis and abdominal cramping as the most common symptoms. This is consistent with a previous study \[[@CR29]\], suggesting that gastrointestinal symptoms should be assessed when considering DIA, and abdominal cramping should especially arouse concern in 0--5-year-old children because they may not accurately express this discomfort.

Epinephrine administration and pediatric DIA {#Sec14}
--------------------------------------------

Similar to our study, the underuse of epinephrine has also been described by previous studies \[[@CR3], [@CR30]\]. As the first-line treatment in anaphylaxis, epinephrine is recommended by primary guidelines \[[@CR21], [@CR26], [@CR28]\]. The low frequency of epinephrine utilization and not using it as the initial therapy in our study could be related to the failure to recognize anaphylaxis initially or the perceived severity of adverse reactions associated with the use of epinephrine. Clinicians should use epinephrine as a first-line therapy as soon as they make a diagnosis of anaphylaxis since delayed epinephrine administration is associated with a risk of hospitalization and poor outcomes \[[@CR2], [@CR8]\].

Our study showed a higher percentage of IV injection (bolus and continuous infusion) but lower intramuscular use. More than two thirds of the administration route was by IV bolus. Studies have found that epinephrine administered by the IM route achieves peak concentrations faster than that given by subcutaneous injection, and IM is also safer than the IV bolus injection \[[@CR4], [@CR27]\]. IV continuous infusion of epinephrine should be preferred when anaphylaxis patients do not respond to repeated IM injections \[[@CR21]\]. The underuse of the IM administration may be because that physicians do not recognize that IM is the optimal route in anaphylaxis treatment, thus further education is needed.

This study showed that the overdosing frequency of epinephrine is quite high, especially with the IV bolus route, which was consistent with a recent study \[[@CR4]\]. Among the 20 supratherapeutic dosing patients, 10 were 0--5 years old, and 13 patients were administered epinephrine exceeding the recommended maximum dose, especially with the IV bolus route. This high frequency of supratherapeutic dosing may be due to (1) the overuse of IV bolus injection, (2) the perceived severity of the anaphylaxis signs and symptoms, (3) physicians not knowing the recommended maximum dose of epinephrine in treating anaphylaxis, especially for the 0--5 year age group, and (4) confusion about the recommended dose treating anaphylaxis with the dose treating cardiac arrests. The fact that only one epinephrine formulation (1:1000, 1 mg/ml) is available in China may also contribute to the high frequency of overdosing.

IV bolus administration of epinephrine should be avoided whenever possible due to the risk of cardiac arrhythmias and potential for inappropriate dosing \[[@CR4]\]. The epinephrine dosing by IV bolus injection in anaphylaxis is also significantly lower than the dose recommended for cardiac arrest (1 mg of 1:10,000) IV bolus \[[@CR7]\]. Caution should be exercised when treating the 0--5-year-old age group especially with an IV bolus as overdosing tends to occur more frequently based on our analysis.

Other common treatments in pediatric patients with DIA {#Sec15}
------------------------------------------------------

Our study observed a higher frequency of corticosteroids use compared to epinephrine use despite corticosteroids is recommended only as second-line adjunctive therapy \[[@CR21], [@CR26], [@CR28]\]. Additionally, when used as the only initial monotherapy, corticosteroid use was approximately two times higher than epinephrine. This discrepancy between practice and guidelines \[[@CR21], [@CR26], [@CR28]\] may be because physicians fail to recognize that epinephrine should be the cornerstone and first-line therapy in anaphylaxis.

Although wheezing and dyspnea symptoms each accounted for about 20% of anaphylaxis in children, only 4% of them were administered inhaled short-acting beta-2 agonists. This suggests that β2-agonist inhalation treatment should be enhanced in anaphylaxis management in order to quickly alleviate lower respiratory tract symptoms. Furthermore, although a previous study showed that the combination of systemic H1- and H2-antihistamines are more beneficial than H1-antihistamine monotherapy in relieving some cutaneous symptoms in those experiencing acute allergic reactions \[[@CR18]\], only 1 of our patients received H2-antihistamines.

Limitations {#Sec16}
-----------

The study has several limitations: (1) the analysis was based on self-reported cases by health care professionals from the BPD, which may include incomplete data; (2) we may not include all DIA pediatric patients: cases missed if clinicians did not report using the terms related to allergy or anaphylaxis or hypersensitivity; and (3) the sample size was small. The method we have taken should be robust against a range of potential biases: rigorous inclusion/exclusion criteria were utilized and all potential anaphylaxis cases were adjudicated by trained physician/allergists; and only patients with complete data record were included in the analysis.

The present study showed there were differences in clinical symptoms and severities of DIA among 0--5, 6--12, and 13--17-year-old patients. For DIA in pediatric patients in the Beijing area, we found that the three common triggers were antibiotics, TCM injections, and biologics. Epinephrine was underused compared to corticosteroids in the treatment of anaphylaxis. IV bolus of epinephrine was overused and was associated with supratherapeutic dosing.
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